Pharmacy

Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.

Consider these five opportunities to help curb one of the biggest public health issues of the year.

An eye-opening Canadian study has surprising findings about the risk of death and antidepressants.

More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.

New physician-administered therapies on the horizon may help rein in the opioid epidemic.

A new study has shocking results about beta blocker use in heart-attack survivors.

This new hospital model offers an opportunity to attract new patients in an efficient, cost-effective setting.

PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.

As more specialty drugs are approved, cost control strategies are key.

Experts share how the declaration could affect how the opioid epidemic is managed.

As the opioid epidemic rages, up-and-coming physicians are seen as part of the solution. Here’s how medical schools are changing their training programs.

New medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.

The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.

An eye-opening study by Precision for Value assesses cancer value frameworks.

Here are three ways HealthPartners’ health plan and care delivery system work together to save customers time and money and improve their experience.

By using a patient-centered, physician-led model of care, Blue Cross Blue Shield (BCBS) of Michigan lowers recidivism and healthcare costs.

An Avalere study has interesting findings about payer acceptance of biosimilars.

Uncover the root causes of why patients become nonadherent and be better positioned to improve the lives of patients and reduce costs through improved health outcomes.

Analysts discuss how pharmacoeconomics will make a difference in treatment decisions.

Payers realize value in partnering with pharmacists to manage medication-related complications

Cost burden prompts payers to consider appropriate utilization

A National Lipid Association survey has interesting findings on the prescription approval process for PCSK9 inhibitors.

To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive conducted its annual pharmacy survey during the first quarter of 2017.

One expert believes managed care executives are key to a necessary paradigm shift in pediatric polypharmacy.

The conference raised important points about unregulated growth opportunities and new pharmacy arena players.